Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Lili Tong & Sharon Adler. (2018) Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgraduate Medicine 130:4, pages 381-393.
Read now
Read now
Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll & Filip K. Knop. (2017) Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opinion on Drug Safety 16:3, pages 351-363.
Read now
Read now
Melanie Davies, Sudesna Chatterjee & Kamlesh Khunti. (2016) The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications 8, pages 61-81.
Read now
Read now
Giorgio Gentile, Daniela Mastroluca, Piero Ruggenenti & Giuseppe Remuzzi. (2014) Novel effective drugs for diabetic kidney disease? or not?. Expert Opinion on Emerging Drugs 19:4, pages 571-601.
Read now
Read now
Malcolm A. Young, Jeffrey A. Wald, Jessica E. Matthews, Rhona Scott, Rebecca J. Hodge, Hui Zhi & Rickey R. Reinhardt. (2014) Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist. Postgraduate Medicine 126:7, pages 84-97.
Read now
Read now
Articles from other publishers (15)
Shweta Urva, Tonya Quinlan, John Landry, Jennifer Martin & Corina Loghin. (2021) Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics 60:8, pages 1049-1059.
Crossref
Crossref
Marie-Noel Rahhal, Naser Eddin Gharaibeh, Leili Rahimi & Faramarz Ismail-Beigi. (2019) Disturbances in Insulin–Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. The Journal of Clinical Endocrinology & Metabolism 104:11, pages 4949-4966.
Crossref
Crossref
Wendy L. St. Peter, Lori Wazny & Joanna Q. Hudson. 2019. Chronic Kidney Disease, Dialysis, and Transplantation. Chronic Kidney Disease, Dialysis, and Transplantation
250
272.e5
.
Charlotte Granhall, Flemming L. Søndergaard, Mette Thomsen & Thomas W. Anderson. (2018) Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clinical Pharmacokinetics 57:12, pages 1571-1580.
Crossref
Crossref
Markolf Hanefeld, Juan M. Arteaga, Lawrence A. Leiter, Giulio Marchesini, Elena Nikonova, Marina Shestakova, William Stager & Ricardo Gómez-Huelgas. (2017) Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes, Obesity and Metabolism 19:11, pages 1594-1601.
Crossref
Crossref
Luca Di Lullo, Michela Mangano, Claudio Ronco, Vincenzo Barbera, Antonio De Pascalis, Antonio Bellasi, Domenico Russo, Biagio Di Iorio & Mario Cozzolino. (2017) The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S295-S305.
Crossref
Crossref
Thomas C. Marbury, Anne Flint, Jacob B. Jacobsen, Julie Derving Karsbøl & Kenneth Lasseter. (2017) Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment. Clinical Pharmacokinetics 56:11, pages 1381-1390.
Crossref
Crossref
Andreas Brønden, Filip K. Knop & Mikkel B. Christensen. (2017) Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics 56:7, pages 719-731.
Crossref
Crossref
Mylène Giraudon, Stefan Sturm, Nathalie Lambert, Markus Niggli, Jochen Brumm, Bernhard Mangold & Christophe Schmitt. (2017) Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. Diabetes, Obesity and Metabolism 19:4, pages 537-544.
Crossref
Crossref
Arun K. Sharma, Punniyakoti V. Thanikachalam & Satyendra K. Rajput. (2016) Albiglutide: Is a better hope against diabetes mellitus?. Biomedicine & Pharmacotherapy 77, pages 120-128.
Crossref
Crossref
Matthew W. Hruska, Robert Adamczyk, Elizabeth Colston, Michael Hesney, Michele Stonier, Heather Myler & Richard Bertz. (2015) The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function. British Journal of Clinical Pharmacology 80:3, pages 515-524.
Crossref
Crossref
Sri Harsha Tella & Marc S. Rendell. (2015) Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Therapeutic Advances in Endocrinology and Metabolism 6:3, pages 109-134.
Crossref
Crossref
Mazen Alsahli & John Gerich. (2015) Hypoglycemia in Patients with Diabetes and Renal Disease. Journal of Clinical Medicine 4:5, pages 948-964.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 54:1, pages 1-21.
Crossref
Crossref
Lawrence A. Leiter, Molly C. Carr, Murray Stewart, Angela Jones-Leone, Rhona ScottFred Yang & Yehuda Handelsman. (2014) Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study. Diabetes Care 37:10, pages 2723-2730.
Crossref
Crossref